FAQ Library

FAQ Library published on August 6, 2018
Dr. Kumar reviews a range of patient- and disease-related factors to consider when choosing therapies for NDMM including; transplant eligibility, renal function, and presence of extramedullary disease
FAQ Library published on July 24, 2018
Dr. Raje explores options for treating smoldering multiple myeloma and explains how approaches in this precursor state hope to prevent progression to myeloma.
FAQ Library published on July 16, 2018
In this video, Dr. McCarthy discusses whether it may become standard of care to use antibiotic prophylaxis in certain patients with multiple myeloma.
FAQ Library published on July 9, 2018
Dr. Raje explains where denosumab fits in the treatment profile for bone disease in multiple myeloma.
FAQ Library published on June 12, 2018
Dr. Kumar reviews what the 2018 approval of daratumumab in combination with the VMP regimen in certain newly diagnosed multiple myeloma patients means for ongoing developments in four-drug regimens.
FAQ Library published on June 4, 2018
Dr. McCarthy explains the specific risks that patients with smoldering myeloma face, and what you need to look for in follow-up monitoring.
FAQ Library published on April 18, 2018
Dr. Raje explains potential toxicities associated with the BCMA-directed CAR T-cell approach vs. transplant in multiple myeloma, highlighting the bb2121 clinical trial.
FAQ Library published on March 28, 2018
Dr. Cohen explains the impact of cytokine release syndrome and neurotoxicity when using BCMA-directed CAR-T cells.
FAQ Library published on February 23, 2018
Dr. Richardson briefly describes how the CD38-targeted monoclonal antibody isatuximab, if approved, may impact treatment selection for patients with relapsed/refractory multiple myeloma.
FAQ Library published on January 24, 2018
Dr. Lonial provides a concise summary of clinical trials and forthcoming data in 2018 that have the potential to change the way we treat multiple myeloma.
Page 3 of 16
Results 21 - 30 of 151